Delivery Order SPE2DB22D3016-SPE2DB25FBCG6
Award Date 7/18/25
Potential Completion Date 7/21/25
Potential Value $5.3K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a $102,781.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with an ultimate completion date of August 6, 2025. This non-set-aside contract was competitively awarded and represents a single delivery order fulfilling federal medical supply requirements. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a $2,527.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 4, 2025, with completion scheduled for September 5, 2025. HEPLISAV-B is a recombinant zoster vaccine indicated for prevention of herpes zoster in adults 50 years of age and older. This non-set-aside award was competitively procured and will be performed at the contractor's location in Conshohocken, Pennsylvania. The delivery order is a...
- The Defense Logistics Agency awarded a $157,217.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes, with a completion date of July 30, 2025. HEPLISAV-B is a recombinant zoster vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 and older. This delivery order represents a non-set-aside, competitively awarded contract utilizing AmerisourceBergen's existing indefinite delivery vehicle with the DLA. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $4,212.40 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This firm fixed-price delivery order is scheduled for completion by September 9, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting AmerisourceBergen's established capability to meet federal...
- The Defense Logistics Agency awarded a delivery order valued at $1,684.96 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 8, 2025, with completion scheduled for September 9, 2025. This delivery order is structured under a firm fixed price contract type with no set-aside designation, indicating competitive award. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as the company's headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...
- The Defense Logistics Agency awarded a delivery order valued at $2,527.44 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 11, 2025, with completion expected by September 12, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and will be performed at AmerisourceBergen's corporate offices in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for immunization of adults 18 years of age and older,...
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The U.S. Defense Logistics Agency awarded a delivery order valued at $14,637.70 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed price delivery order was issued without a set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention...
- The Defense Logistics Agency awarded a $120,474.64 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This competitively awarded, firm fixed-price contract with no set-aside designation is scheduled for completion by July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adult immunization, representing part of the Defense...